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INTRODUCTION
Adequate dosage and administration of vancomycin as well
as monitoring of its concentration, especially at the begin-
ning of vancomycin therapy, is important in treating bacte-
rial infections.
Monitoring of vancomycin concentration in serum is a
widely used practice worldwide that helps to evaluate the
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There have been a limited number of studies in Latvia that were focused on vancomycin thera-
peutic drug monitoring (TDM), especially during the initiation phase of the therapy. The aim of this
study was to investigate details of vancomycin therapy in its initiation phase and to analyse the
results of the first therapeutic drug monitoring within a multidisciplinary hospital in Latvia. A retro-
spective observational study was performed in a multidisciplinary hospital in Latvia. Adult patients
hospitalised in an intensive care unit and undergoing vancomycin therapy with at least one con-
centration measurement were included in this study. Data about patients included demographic
and clinical data, renal function prior to initiation of vancomycin therapy, data about vancomycin
therapy, data about the first TDM, and details about the first measurement of vancomycin con-
centration according to determined reference range — subtherapeutic, therapeutic and
supratherapeutic levels. A total of 60 intensive care unit patients who received vancomycin with at
least one concentration measurement were included in this study. Fifty-eight patients received
vancomycin as intermittent intravenous infusion. The first measurement of concentration was
taken before the 3rd–4th vancomycin dose in 38.3% cases, and in 33.3% cases — before the 2nd
dose. Sampling to determine the concentration within 30 minutes before vancomycin administra-
tion was performed in zero cases. In 35% cases, sampling was done within 2–5 hours before
vancomycin administration and in 23.3% — immediately after or within a few hours after
vancomycin infusion. Twelve (20%) patients had a concentration in the subtherapeutic level, and
14 (23.3%) patients had concentrations above the therapeutic level. In 42.8% of patients who had
concentrations in supratherapeutic level, sampling had been performed immediately after or
within several hours after vancomycin administration. The first concentration measurement was
performed more than one hour before an infusion in all cases. Data on concentrations and timing
were not adequate to perform appropriate therapy modification. Interpretation of dosing regime
and concentration results were not adequate, and therefore correct modification of vancomycin
therapy was often not possible. Routines of correct dosing regime and the 1st TDM during the ini-
tiation phase of vancomycin therapy can be improved.
Key words: concentration measurement, narrow therapeutic range, antibacterial agents, mini-
mum inhibitory concentration.
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direction of vancomycin therapy and make necessary ad-
justments (Gould et al., 2012; Tabah et al., 2015; Bakke et
al., 2017; Hanberger, 2017).
Due to many factors, reaching a therapeutic level of
vancomycin is rather difficult for patients in hospitals, par-
ticularly for those in intensive care (Revilla et al., 2010). An
individual approach is necessary in such cases, including
therapy adjustments based on vancomycin TDM, including
for patients with oral vancomycin (McDonald et al., 2018).
Vancomycin is a time-dependent antibiotic. Its administra-
tion should always be scheduled before the concentration
has decreased to below the minimum inhibitory concentra-
tion (MIC) level (Rybak, 2006). Vancomycin concentration
below the MIC level can result in increased risk of micro-
bial resistance (Estes and Derendorf, 2010). It is important
that sampling to determine its concentration is performed
immediately before vancomycin infusion (Rybak et al.,
2009; Hammond et al., 2017).
Vancomycin doses and the dosing regimen should be deter-
mined before the initiation of therapy. The severity of in-
fection, body weight, age and renal function should be taken
into consideration. Also, administration of further mainte-
nance doses after the first loading dose are recommended
(Rybak et al., 2009; Bakke et al., 2017; Hanberger, 2017, at
pp. 57–161).
In case of renal impairment, elimination of vancomycin de-
creases and accumulation is observed (De Gatta Garcia et
al., 2007). Therefore, reduced maintenance doses or longer
dosing intervals are needed (Barber et al., 2016; Hanberger,
2017, at pp. 57–161). However, a contradictory tendency
has been observed in obese patients (Grace, 2012) and in
patients with augmented renal function (Tabah et al., 2015).
In cases of intermittent vancomycin infusion, the first TDM
before the 3rd or 4th dose is recommended for patients with
normal renal function (Rybak et al., 2009; Zamoner et al.,
2019). If the vancomycin concentration is outside its thera-
peutic range, the therapy should be adapted accordingly
(Tafelski et al., 2015).
The purpose of this study was to investigate the details of
vancomycin therapy in its initiation phase and analyse the
results of the first therapeutic drug monitoring within a
multidisciplinary hospital in Latvia.
The target data for analysis were:
1. Initial doses and dosing regimens of vancomycin be-
fore the first TDM;
2. Results of the 1st TDM of vancomycin;
3. Vancomycin dosing tactics in cases of abnormal
vancomycin plasma concentrations.
MATERIALS AND METHODS
The retrospective observational study was performed in a
multidisciplinary hospital in Latvia. Sixty patients in an in-
tensive care unit (ICU) on vancomycin therapy with at least
one concentration measurement were included in this study.
The study was approved in Ethical Committee of Rîga Stra-
diòð University, approval No. 38/26.10.2017.
Data on patients were obtained from the digital database of
the hospital laboratory and archived medical records. The
data included vancomycin concentration measurements per-
formed during the period of 01.12.2016–30.09.2017.
Adult patients older than 18 years of age, hospitalised in the
ICU, were included in this study.
Patient data were categorised as following:
1. Demographic and clinical data: gender, age, weight,
body mass index (BMI), duration of hospitalisation,
mortality, creatinine clearance, Glomerular Filtration
Rate (GFR).
2. Renal function prior to vancomycin therapy: patients
with normal renal function GFR 60 mL/min/1.73
m2 (augmented renal function (GFR > 130); normal
renal function (GFR 60–130)); patients with impaired
renal function GFR 60 mL/min/1.73 m2 (moderate
impairment (Stage 3) – Stage 3a (GFR 45–59), Stage
3b (GFR 30–44)); severe renal impairment (Stage 4)
(GFR 15–29); renal failure (Stage 5) (GFR < 15 or
dialysis)).
3. Data on vancomycin therapy: duration, cases of em-
pirical therapy, indication, result of vancomycin con-
centration, administration (peroral or intravenous,
continuous or intermittent, dosage regime prior to the
first concentration measurement, duration of infu-
sion).
4. Data on the first TDM and the division of TDM
groups: Group 1 (the 1st TDM performed prior to the
2nd vancomycin dose), Group 2 (the 1st TDM per-
formed prior to the 3rd or 4th dose), Group 3 (the 1st
TDM performed prior to the 5th–9th dose), Group 4
(the 1st TDM performed immediately after or several
hours after the vancomycin administration).
5. Details about vancomycin concentration according to
determined reference ranges: subtherapeutic, thera-
peutic and supratherapeutic levels, and tactics on
therapy adjustment after the 1st TDM.
Descriptive statistical method was used for data analysis.
Means (M) and standard deviations (SD) were used for
quantitative assessment of normally distributed data. Data
which did not comply with data normalisation, median (Me)
and interquartile ratio [IQR] were applied. Verification of
data distribution was performed with the Kolmogorov–
Smirnov test. For processing qualitative data, the Pearson’s
chi-squared statistical test was performed if the expected
values in the contingency table were 5. Additionally, the
Fisher's exact test was used if expected values were < 5.
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RESULTS
Of the 60 study patients, 29 (48.3%) were women and 31
(51.7%) were men. Age was consistent with a normal distri-
bution and M and SD (min-max) were 58.5; 12.3 (23–85)
years (p = 0.20), respectively. The average hospitalisation
length did not comply with a normal distribution; Me;
[IQR] (min-max) were 27.0; [19.3] (4–66) days (p = 0.03).
Hospitalisation of 24 (40%) patients was planned before
hospitalisation. The survival rate was 60% (36 patients).
Twenty (33.3%) patients had previously available records
of weight and height. Body mass in these patients was: M;
SD (min-max) = 88.75; 5.1 (61–210) kg (p = 0.2). The
mean BMI (min-max) was 30.4; 5.1 (18.2–39.5) kg/m2 (p =
0.14). Four (20%) patients were overweight, 12 (60%) pa-
tients were adipose (Grade 1 — 9 (45%) patients; Grade
2 — 3 (15%) patients). Data on vancomycin therapy and
vancomycin concentration are presented in Table 1.
Twenty-four (40%) patients had normal renal function (in-
cluding augmented renal function in 8 (33.3%) cases). Mod-
erately impaired renal function or severe renal impairment
was observed in 38 (60%) patients.
Fifty-eight (96.7%) patients received vancomycin intrave-
nously as intermittent infusion. Two (3.3%) patients re-
ceived vancomycin orally.
The Pearson’s chi-square test showed a statistically signifi-
cant association between normal renal function and the
choice of vancomycin dose (p = 0.001). Patients with nor-
mal renal function in 12 cases (20.7%) received 1000 mg
vancomycin every 12 h. Twenty-five (43.1%) patients with
renal impairment received 1000 mg vancomycin every 24 h.
Vancomycin dose did not exceed 2000 mg in total.
In all intravenous vancomycin cases, it was administered at
least for one or more hours of infusion. One-hour infusion
was performed in 43 (74.1%) cases (16 (27.6%) with nor-
mal renal function, and 27 (46.6%) with renal impairment).
Given that the number with infusions exceeding two hours
was too small, those cases were excluded in Fisher’s test. In
analysis of 1–2 h infusions, Fisher’s test showed no associa-
tion between the duration of infusion and renal function.
Vancomycin dosages depending on renal function prior to
the first concentration sampling and the first therapeutic
drug monitoring are summarised in Table 2. The first TDM
was performed for all 60 patients. Concentrations for two
patients with oral vancomycin were also included in proc-
essing of data of concentration measurements. However,
data on these patients were excluded from the calculations
specific only for patients with parenteral vancomycin.
The first concentration measurement was performed before
the 3rd or 4th dose in 38.4% cases, and before the 2nd vanco-
mycin dose — in 20 (33.3%) cases. The first TDM within
30 minutes or less prior to vancomycin administration was
performed in zero cases. Sampling immediately after or a
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Table 1. Justification and duration of vancomycin therapy
Parameters Values





Empiric vancomycin therapy, n (%) 42 (70%)









Methicillin-susceptible S. aureus sepsis

















Concentration of vancomycin in serum*
5–15 µg/ml**, n (%)
15–20 µg/ml (recommendations of infectologist), n (%)
57 (95%)
3 (5%)
* Reference interval of vancomycin concentration required for a patient.
** Reference interval of vancomycin concentration of hospital laboratory
during the study.
Table 2. Renal function and dosage of vancomycin prior the 1st TDM
Parameter Patients with normal renal
function (n = 25)
Patients with renal impairment,
including renal insufficiency,
dialysis (n = 33)
p value
Dosage of vancomycin prior the 1st TDM
Dose of vancomycin
1000 mg every 48 hours, IV, n (%)
1000 mg every 24 hours, IV, n (%)
1000 mg every 12 hours, IV, n (%)



























few hours after vancomycin administration was done in 14
(23.3%) cases. The 1st measurement before the 3rd or 4th
doses was done for eight (13.3%) patients with normal renal
function and for 15 (25%) patients with renal impairment.
Concentration measurement before the 2nd dose was per-
formed for six (10%) patients with normal renal function
and for 14 (23.3%) patients with renal impairment. The 1st
concentration measurement was performed immediately af-
ter or a few hours after vancomycin administration in 14
(23.3%) cases, for ten patients with normal renal function
and for four patients with renal impairment.
All samples performed prior to the vancomycin administra-
tion were obtained more than 1 hour (period between
13 h–1 h 11 min) before vancomycin infusion. Sampling
prior to the 3rd or 4th dose (Group 2) was taken over a peri-
od of 12 h 52 min –1 h 11 min prior to the vancomycin ad-
ministration. Concentration measurements were taken bef-
ore the 2nd dose (Group 1) (period 13 h – 1 h 42 min before
infusion) in 20 (33.3%) cases. The first concentration meas-
urement immediately or within few hours after initiation or
completion of vancomycin administration (Group 4) (inter-
val from 5 minutes after the beginning of an infusion to 4 h
18 min after completion of administration) was done for 14
(23.33%) patients.
The first TDM before the 2nd dose was performed for 12
(20%) patients with severe renal impairment (Group 1). In
Group 2, eight (13.3%) patients had GFR 60 ml/min/1.73
m2, and 25 (25%) patients had GFR 60 ml/min/1.73 m2.
The Pearson’s chi-square test showed a statistically signifi-
cant association between normal renal function and timing
(before vancomycin dose) of the 1st TDM (p = 0.036). Ten
(16.67%) patients in Group 4 had GFR 60 ml/min/1.73
m2. Renal function in each TDM group is presented in Fig-
ure 1.
In Groups 1, 2 and 3 (46 (76.7%) patients), vancomycin
concentration in eight (13.3%) cases was < 5 µg/ml, in 28
(46.7%) cases 5–15 µg/ml, and in ten (16.7%) cases > 15
µg/ml. In three cases, an infectologist had recommended
vancomycin concentration within 15–20 µg/ml as a thera-
peutic level, therefore one case (10.09 µg/ml) was classified
as subtherapeutic and two cases (16.4 and 19 µg/ml) as a
therapeutic level. The Kolmogorov–Smirnov test showed
that concentration values in each range (subtherapeutic,
therapeutic, supratherapeutic) did not comply with normal-
ity, and therefore the value for each range was calculated
using Me; [IQR].
The first measurement of concentration in nine (15%) cases
was in the subtherapeutic range M; [IQR] — 2.68 [0.97]
µg/ml. Two patients had GFR 60 mL/min/1.73 m2 (41 and
47 ml/min/1.73 m2, respectively) (the latter patient had a
recommendation of therapeutic concentration within a
15–20 µg/ml range). Seven patients had GFR 60
ml/min/1.73 m2 (three patients had GFR > 130 ml/min/1.72
m2). In three of nine cases, concentration measurement was
performed prior to the 2nd vancomycin dose. After receiv-
ing the results of subtherapeutic concentrations, a doctor did
not change the vancomycin dose nor dosing interval in four
cases (all from Group 1). A doctor shortened the dosing in-
terval in five (8.3%) cases (all cases in Group 2 and Group
3).
Concentration measurements for 29 (48%) patients were
within the therapeutic range (M; [IQR] = 9.33 [5.47]
µg/ml). An infectologist had recommended a therapeutic
level of 15–20 µg/ml for two patients. These patients were
included in this category, although the vancomycin concen-
tration was 16.04 and 19 µg/ml, respectively. Six (10%) pa-
tients had GFR 60 ml/min/1.73 m2, and 23 (38.3%) pa-
tients had GFR 60 ml/min/1.73 m2. A doctor did not
modify the dose, nor dosing interval for 17 (28.3%) pa-
tients. The dosing interval was shortened for three patients,
and there was a dose reduction for three patients.
The first concentration exceeding the upper limit of the ref-
erence interval (supratherapeutic range; above the labora-
tory reference > 15 µg/ml or recommendation by an
infectologist > 20 µg/ml) was observed in eight cases. The
mean concentration (M; [IQR]) for the supratherapeutic
range was 19.22; [5.98] µg/ml. Sampling before the 4th dose
was performed in all cases. The vancomycin dose was re-
duced in one case, and in two cases the dosing interval was
extended. No therapy modification was applied in five
cases.
Vancomycin concentration data in TDM Groups 1, 2 and 3
are summarised in Figure 2.
In 14 (23%) cases (Group 4) analysis of vancomycin con-
centration was taken immediately after initiation of vanco-
mycin infusion or within a few hours after administration.
Therefore, results of Group 4 were excluded from Figure 2.
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Fig. 1. Division of TDM groups and renal func-
tion.
DISCUSSION
This study showed that in all cases of intravenous admini-
stration only intermittent infusions were performed. These
data are consistent with other publications — in most cases
vancomycin is administered as an intermittent intravenous
infusion (Tabah et al., 2015). Continuous infusions are
thought to be better in terms of drug safety (Hao et al.,
2016), but medication incompatibilities with vancomycin
should be taken into consideration (Raverdy et al., 2013).
In this study, in all cases vancomycin was administered for
at least one-hour long infusion. This is a good approach in
order to reduce potential risks of vancomycin side effects
(Bauer, 2008, at pp. 207–298; Rybak et al., 2009). Also, in
this study, vancomycin was administered as an infusion
over several hours. However, more research is required to
define the benefits of such prolonged intermittent infusion
schemes.
It was not possible to assess the general strategy of the 1st
vancomycin dose — whether it was a maintenance dose or a
loading dose. The same refers to the strength of the 1st dose.
Usually a loading dose is recommended for initiation of
vancomycin therapy. The purpose of such a strategy is to
reach the necessary therapeutic concentration earlier (Rybak
et al., 2009; Bakke et al., 2017; Hanberger, 2017, at pp.
57–161; Ye et al., 2016).
Only 33.3% of patients in this study had available records
of weight and height in medical documentation. The ab-
sence of these data creates an obstacle in utilising the load-
ing dose, as it is usually calculated based on body weight
not taking into consideration renal function in most of the
cases (Tafelski et al., 2015). In literature, the recommended
loading dose of vancomycin is 25–30 mg/kg (Álvarez et al.,
2016; Hanberger, 2017, at pp. 57–161). Following the load-
ing dose, therapy is usually continued with a maintenance
dose 15–20 mg/kg two or three times a day (Hanberger,
2017, at pp. 57–161). Therefore, correct dosing calculations
during the initial phase of vancomycin therapy would have
been possible only for patients having records of weight and
height.
More than a half (60%) of the patients with weight and
height measurements had Grade 1 or 2 adiposity. Achieving
the appropriate vancomycin concentration and maintaining
it within the therapeutic range is highly important especially
for adipose patients (Grace, 2012), (Álvarez et al., 2016;
Kane and Hanes, 2017). Also, low concentrations of
vancomycin are associated with selection of partially or
fully resistant strains (Rybak et al., 2009; Marquis et al.,
2015). In contrast, excess vancomycin accumulation in re-
nal impairment may cause toxicity (Del Mar Fernandez De
Gatta Garcia et al., 2007).
TDM for patients with normal or partially impaired renal
function immediately before the vancomycin infusion is the
most practical method for monitoring vancomycin therapy.
Sampling should be performed before the 3rd or 4th vanco-
mycin dose (Rybak et al., 2009; Tafelski et al., 2015; Za-
moner et al., 2019). In our study, the first TDM was per-
formed before the 3rd–4th dose in 38.3% cases. The first
TDM was performed before the 2nd dose in 33.3% cases,
which might be too early. A sufficient time is required for
vancomycin to reach a steady-state concentration (Martin,
2010). Such an approach might have been applied to iden-
tify early problems of renal function. Furthermore, results
from similar studies have been shown to be reported errone-
ously. This would cause problems in correct vancomycin
therapy modification. A Norwegian study indicated that
70–80% of concentration results failed to reach therapeutic
concentrations during the first three days of therapy (Bakke
et al., 2017). This is a significantly higher incidence rate
than in our study. Incorrect levels of concentration may be
associated with inappropriate timing of concentration sam-
pling prior to vancomycin infusion (Traugott et al., 2011).
Too early sampling prior to the infusion can result in misin-
terpretation of TDM results, leading to incorrect adjustment
of vancomycin therapy (Morrison et al., 2018). Therefore, it
is important that sampling is done right before the admini-
stration of vancomycin (within 30 minutes, max 60 minutes,
before scheduled vancomycin administration) (Morrison et
al., 2018). Another retrospective study was conducted in
Brigham and Women's Hospital, Boston (Morrison et al.,
2018). The study group discovered that in 41.3% of cases,
sampling was performed too early (Morrison et al., 2018).
A similar outcome was confirmed in this study. TDM was
done too early and none of concentration measurements
were obtained within 30 minutes or within 1 hour prior to
vancomycin administration.
At the time of this study, the vancomycin reference range in
the hospital laboratory was 5–15 µg/ml. Interpretation of the
concentration levels in this study was made in accordance
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Fig. 2 . Values of vancomycin concentrations.
with the reference standards of the laboratory. Also, there
were three patients in our study with infectologist’s recom-
mendations. For those patients, a therapeutic reference in-
terval was defined as 15–20 µg/ml. As a result, only 20% of
patients in this study had subtherapeutic concentrations. The
lowest vancomycin concentration in publications is recom-
mended as 10 µg/ml, and a therapeutic concentration of
vancomycin as 15–20 µg/ml (Rybak et al., 2009; Bakke et
al., 2017; Tong et al., 2020). If reference intervals of the
hospital laboratory were more harmonised, the results
would have likely been similar to those of Bakke et al.
(Bakke et al., 2017). In this study the Me [IQR] concentra-
tion in the therapeutic range, was 9.33 [5.47] µg/ml. This in-
dicates that concentrations often were too low and raising
concern that concentrations µg/ml could lead to increased
resistance (Bakke et al., 2017).
10% of patients had augmented renal function with GFR
130 ml/min/1.73 m2. These patients have much higher risk
of vancomycin being in subtherapeutic concentrations (Bap-
tista et al., 2012). Results of this study correlate with other
publications where patients with augmented renal function
also had lower vancomycin concentrations (Dolton et al.,
2010; Bakke et al., 2017; Morbitzer et al., 2016; Campassi
et al., 2014).
After receiving the results of subtherapeutic concentrations,
dose adjustments were made in five cases while the therapy
was not changed in four cases. In one case, the first TDM
was performed only before the 5th dose. If the blood sample
would have been taken earlier, subtherapeutic concentra-
tions would have been detected and therapy adjustments
performed sooner.
In 23.3% of all cases concentrations exceeded therapeutic
concentrations and in 42.8% of these cases sampling was
performed either immediately or within few hours after van-
comycin infusion. In fact, concentration levels in such cases
would be more preferably defined as the maximum (close to
maximum) level. For patients with severe renal impairment
or renal insufficiency, administration of continuous infusion
could be considered in order to decrease nephrotoxicity risk
(Jeffres, 2017). However, a previous study did not indicate
an association between continuous infusion and a lower risk
of nephrotoxicity (Sokolova and Sabelnikovs, 2013). New
approaches, such as the AUC (Area Under the Curve) / MIC
ratio could be considered for more precise vancomycin ther-
apy (Aljefri et al., 2019; Holmes, 2020; Rybak et al., 2020).
In this study, the dosing interval was shortened for 56% of
patients with subtherapeutic concentrations, and prolonged
dosing intervals were applied for 37% of patients with su-
pratherapeutic concentrations. No therapy adjustments were
made for the remaining cases, despite inappropriate concen-
trations.
CONCLUSION
1. First doses and dosing regimens of vancomycin might not
have been adjusted correctly in most of the cases.
2. The 1st TDM before the 3rd–4th dose was performed in a
low number of cases. The 1st TDM was done too early and
none of the concentration measurement were obtained
within the suggested time frame in literature prior to vanco-
mycin administration. In almost half of the cases, the vanco-
mycin concentration was in the therapeutic level. However,
since the reference range of vancomycin in the laboratory
was 5–15 µg/ml at the time of this study the therapeutic
level practically would not have been reached. The median
concentration results confirm these concerns.
3. The strategy of vancomycin dosing after the 1st TDM if
outside therapeutic concentrations was often inconsistent
and could be improved.
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VANKOMICÎNA TERAPIJAS UZSÂKÐANA UN PIRMREIZÇJAIS TERAPEITISKAIS ZÂÏU MONITORINGS
Dati par antibakteriâlo lîdzekïu terapijas pielâgoðanas niansçm Latvijâ, pamatojoties uz terapeitisko zâïu monitoringu (TZM), îpaði terapijas
sâkumâ, ir pieejami nelielâ daudzumâ. Pçtîjuma mçríis bija noskaidrot vankomicîna terapijas uzsâkðanas nianses un analizçt pirmreizçjâ
terapeitiskâ zâïu monitoringa rezultâtus daudzprofila slimnîcâ Latvijâ. Retrospektîvs novçrojuma pçtîjums tika veikts vienâ no daudzprofila
slimnîcâm Latvijâ. Pçtîjumâ tika iekïauti pacienti, kuri hopitalizçti intensîvâs terapijas nodaïâ un kuriem uzsâkta vankomicîna terapija ar
vismaz vienu veiktu vankomicîna koncentrâcijas mçrîjumu serumâ. Pçtîjumâ par pacientiem tika ievâkti ðâdi dati: demogrâfiskie un
klîniskie dati; nieru funkcijas râdîtâji pirms vankomicîna terapijas uzsâkðanas; dati par vankomicîna terapijas niansçm, pirmreizçjo TZM
(terapeitisko zâïu monitoringu), koncentrâciju mçrîjumu atbilstîbu subterapeitiskajam, terapeitiskajam vai supraterapeitiskajam lîmenim.
Pçtîjumâ tika iekïauti 60 pacienti, kuri bija stacionçti intensîvâs terapijas nodaïâ. 70% pacientu vankomicîna terapija bija uzsâkta empîriski.
58 pacientiem medikaments ievadîts intermitçjoðas, vismaz vienu stundu ilgas, intravenozas infûzijas veidâ. 38,3% pacientiem pirmais
vankomicîna koncentrâcijas mçrîjums tika veikts pirms 3.–4. devas, 33,3% pacientiem — pirms 2. vankomicîna devas. Nevienam no
pacientiem koncentrâcijas analîze netika paòemta 30 minûðu laikâ pirms vankomicîna ievadîðanas. 21 (35%) pacientam koncentrâcijas
mçrîjums bija veikts 5–2 h lîdz vankomicîna ievadîðanas sâkumam. 23,3% gadîjumos koncentrâcijas analîze tika paòemta uzreiz vai daþu
stundu laikâ pçc vankomicîna ievadîðanas. 12 (20%) pacientiem pirmajâ mçrîjumâ vankomicîna koncentrâcija bija subterapeitiskajâ lîmenî.
14 (23,3%) pacientiem koncentrâcija pârsniedza terapeitisko koncentrâciju — 42,8% gadîjumos deva tika paòemta uzreiz vai daþu stundu
laikâ pçc vankomicîna infûzijas. Pirmreizçjâ asins analîze visos gadîjumos tika paòemta vairâk nekâ vienu stundu pirms vankomicîna
ievadîðanas. Analîþu rezultâti nav pietiekami pareizi interpretçjami, lai varçtu veikt atbilstoðu vankomicîna terapijas pielâgoðanu.
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